- Home
- ZENA vs PRLD Comparison
ZENA vs PRLD Comparison
Compare ZENA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENA
- PRLD
- Stock Information
- Founded
- ZENA 2017
- PRLD 2016
- Country
- ZENA Canada
- PRLD United States
- Employees
- ZENA N/A
- PRLD N/A
- Industry
- ZENA
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- ZENA
- PRLD Health Care
- Exchange
- ZENA NYSE
- PRLD Nasdaq
- Market Cap
- ZENA 82.4M
- PRLD 73.7M
- IPO Year
- ZENA N/A
- PRLD 2020
- Fundamental
- Price
- ZENA $2.12
- PRLD $0.68
- Analyst Decision
- ZENA
- PRLD Strong Buy
- Analyst Count
- ZENA 0
- PRLD 2
- Target Price
- ZENA N/A
- PRLD $4.50
- AVG Volume (30 Days)
- ZENA 610.9K
- PRLD 262.9K
- Earning Date
- ZENA 01-01-0001
- PRLD 05-06-2025
- Dividend Yield
- ZENA N/A
- PRLD N/A
- EPS Growth
- ZENA N/A
- PRLD N/A
- EPS
- ZENA N/A
- PRLD N/A
- Revenue
- ZENA $1,364,714.00
- PRLD $7,000,000.00
- Revenue This Year
- ZENA N/A
- PRLD N/A
- Revenue Next Year
- ZENA N/A
- PRLD N/A
- P/E Ratio
- ZENA N/A
- PRLD N/A
- Revenue Growth
- ZENA 7.43
- PRLD N/A
- 52 Week Low
- ZENA $1.41
- PRLD $0.63
- 52 Week High
- ZENA $12.43
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- ZENA N/A
- PRLD 41.05
- Support Level
- ZENA N/A
- PRLD $0.71
- Resistance Level
- ZENA N/A
- PRLD $0.76
- Average True Range (ATR)
- ZENA 0.00
- PRLD 0.07
- MACD
- ZENA 0.00
- PRLD 0.01
- Stochastic Oscillator
- ZENA 0.00
- PRLD 16.87
About ZENA ZENATECH INC
ZenaTech Inc is a enterprise software technology company that specializes in mission-critical cloud-based applications integrated with smart hardware to deliver innovative solutions across diverse industries. The Company operates in software development technology, sales, and distribution. The Company is also developing a drone manufacturing, sales, and distribution business. The company operates in two segments which is software development technology, sales, and distribution, as well as drone manufacturing, sales, and distribution.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.